Patent Cross-Licensing

Defensive cross-license

Two companies operating in the same technology space each hold patents the other's products likely infringe. Rather than sue and counter-sue into mutual destruction, they grant each other licenses — buying freedom to operate and detente. Common between large technology and electronics companies whose products overlap heavily.

Settlement cross-license

The most common ending to patent litigation between two operating companies: the suit resolves with a mutual license (often plus a balancing payment), dismissing the case and immunizing both sides going forward. Cheaper and more certain than a verdict, and avoids an injunction risk to either party.

Standards / FRAND cross-license

Holders of standard-essential patents frequently cross-license their SEP portfolios so each can implement the standard — sometimes bilaterally, sometimes through a patent pool. Subject to FRAND obligations and antitrust scrutiny.

Strategic / fee-bearing cross-license

Where one portfolio is clearly stronger or one party uses more of the other's technology, the cross-license includes a balancing payment (lump sum or running royalty) flowing to the stronger party. The license is mutual; the money is one-directional.

Scope of the grant

Which patents are licensed — the parties' entire current portfolios, only patents in a defined field, only patents reading on certain products? Broad 'all patents' grants are simple but give away rights in unrelated fields; narrow grants require precise definitions and risk leaving gaps.

Capture period (future patents)

Does the license cover only patents existing at signing, or also patents filed/issued during a 'capture period' (e.g., the next 5 years)? Capture clauses provide longer peace but mean licensing technology you haven't invented yet. A common negotiation flashpoint.

Balancing payment

When portfolios or usage are unequal, a payment from the net licensee to the net licensor evens the exchange. Sizing it requires valuing both portfolios against both product lines — the analytical heart of a fee-bearing cross-license.

Field-of-use and territory limits

Cross-licenses are often restricted to defined fields (so a competitor in one market doesn't gain rights in another) and territories. Precise field definitions prevent the license from leaking value into businesses the grantor wants to protect.

Assignment and change of control

What happens if one party is acquired? Without careful drafting, a competitor could acquire a small company purely to inherit a broad cross-license into a rival's portfolio. Change-of-control and assignment clauses, and 'acquired entity' carve-outs, address this.

Have-made and affiliate rights

Does the license extend to the licensee's contract manufacturers ('have-made' rights) and subsidiaries/affiliates? Supply chains depend on these extensions; their scope is heavily negotiated, especially the definition of 'affiliate' and how it tracks ownership changes.

What is a patent cross-license?

A patent cross-license is an agreement in which two (or more) parties each grant the other a license under some or all of their patents. Instead of one party paying another for a one-way license, both parties exchange rights — each gaining the freedom to practice the other's patented technology. Cross-licensing is one of the most important mechanisms in real-world patent practice, especially among technology, electronics, semiconductor, telecommunications, and automotive companies whose products inevitably overlap with each other's patents. Why it happens: in densely patented fields, any sophisticated company's products likely infringe some patents held by its competitors, and vice versa — a situation of mutual exposure. Litigating every overlap would be ruinously expensive and risky (each side faces injunction and damages exposure), so the rational resolution is often a mutual license that gives both sides freedom to operate and removes the threat of suit between them. Common forms: (1) defensive cross-licenses between competitors to achieve detente; (2) settlement cross-licenses that end litigation; (3) FRAND/standards cross-licenses among standard-essential patent holders; and (4) fee-bearing cross-licenses where a balancing payment flows to the party with the stronger portfolio or whose technology is used more. The deal can be royalty-free (a pure exchange of rights) or include a balancing payment; broad (entire portfolios) or narrow (defined fields or products); and limited to existing patents or extended to future patents within a capture period. Because cross-licenses involve competitors agreeing on terms, they also sit within antitrust limits — legitimate mutual licensing is pro-competitive, but a cross-license cannot be a cover for price-fixing, market division, or excluding rivals.

Why do companies cross-license instead of litigating?

Because in densely patented industries, mutual cross-licensing is usually cheaper, faster, and less risky than fighting — for both sides. The logic: (1) Mutual exposure creates a stalemate. When Company A's products likely infringe some of Company B's patents AND Company B's products likely infringe some of Company A's, neither can sue without facing a powerful counter-suit. This mutual-assured-destruction dynamic pushes both toward a negotiated peace. (2) Litigation is enormously expensive and uncertain. Full patent litigation can cost millions per case and take years, with outcomes (including potential injunctions that could shut down product lines) that neither side can fully predict. A cross-license converts that uncertainty into a defined, bounded arrangement. (3) Freedom to operate has positive value. Beyond avoiding litigation costs, a cross-license affirmatively clears the path to build and ship products without the overhang of infringement risk — valuable for product planning, financing, and customer assurance. (4) Portfolios are bargaining chips. This is a major reason companies accumulate large patent portfolios in the first place: not necessarily to sue, but to have enough patents that any competitor will need a cross-license, giving the company a seat at the table and leverage to negotiate balanced terms. A thin portfolio means paying cash; a strong portfolio means trading rights. (5) Settlement efficiency. When litigation does start, a cross-license is the most common endpoint for suits between two operating companies — it resolves the present dispute and prevents future ones. The main exception to the cross-licensing dynamic is the non-practicing entity (NPE): an NPE makes no products, so it has no exposure to a counter-suit and cannot be deterred by the defendant's portfolio — which is precisely why NPEs are immune to the cross-licensing detente that disciplines disputes between operating companies, and why they are handled with different tools (IPR, litigation, defensive aggregators).

How is a balancing payment in a cross-license determined?

A balancing payment (sometimes called a balancing royalty or true-up) is cash that flows from one party to the other when the value exchanged in a cross-license is unequal — and sizing it is the analytical core of a fee-bearing cross-license. The exchange is unequal when, for example, one party's portfolio is stronger or broader, or one party uses more of the other's patented technology in higher-revenue products. The valuation approach, conceptually: (1) Value each side's relevant patents as applied against the OTHER side's products. The question is not 'whose portfolio is bigger' in the abstract, but how much each party's patents are worth as a license to the other party's actual business — which patents read on which products, generating what royalty base. (2) Net the two figures. If A's patents are worth $X as a license to B's products, and B's patents are worth $Y as a license to A's products, the balancing payment is roughly the difference (X − Y), paid by the net licensee to the net licensor. (3) Choose a structure for the payment: a lump sum, a running royalty on the net licensee's relevant sales, or a combination — each with different risk allocation and accounting consequences. In practice the analysis is heavily negotiated and imprecise: it draws on the same reasonable-royalty concepts used in patent damages (comparable licenses, apportionment to the patented features, the smallest salable patent-practicing unit), expert portfolio assessments, and each side's leverage. Many cross-licenses end up royalty-free (a 'wash') when the parties judge the portfolios roughly balanced, accepting some imprecision in exchange for avoiding an expensive valuation fight. The balancing payment is where a cross-license shifts from pure detente to a commercial transaction, and it is typically the most contested term.

What is a capture period in a cross-license?

A capture period defines which patents are included in a cross-license based on time — specifically, whether the license covers only patents that exist at signing, or also patents that the parties file or that issue during a defined future window. The issue arises because a cross-license is meant to provide lasting peace, but technology and portfolios keep evolving: a license covering only today's patents may leave the parties exposed to each other's NEW patents next year, reviving the very conflict the cross-license was meant to end. Common approaches: (1) Existing patents only — the license covers patents issued or filed as of the effective date. Simplest, but provides the shortest peace; new patents are unlicensed. (2) Capture period — the license also covers patents with priority/filing dates (or issue dates) within a defined period, often the first few years of the agreement (e.g., 'patents having an effective filing date on or before the fifth anniversary'). This extends the freedom-to-operate horizon. (3) Term-long capture — the license covers patents arising at any time during the agreement's term. Longest peace, but means licensing technology neither party has invented yet, which the party expecting to out-innovate the other may resist. The capture period is a frequent negotiation flashpoint precisely because it allocates the value of FUTURE innovation: a company that expects to develop breakthrough technology during the period wants a short capture window (so it can separately monetize its new patents), while the counterparty wants a long window (so it isn't blocked by the other's future patents). Related drafting includes how capture interacts with continuations and divisionals (which claim earlier priority dates) and with patents acquired from third parties during the period (often excluded, to prevent a party from buying patents specifically to assert around the cross-license).

Are cross-licenses subject to antitrust limits?

Yes. Cross-licenses are generally pro-competitive and lawful — the DOJ/FTC Antitrust Guidelines for the Licensing of Intellectual Property recognize that cross-licensing can integrate complementary technologies, clear blocking positions, reduce transaction costs, and avoid litigation, all of which benefit competition and consumers. But because a cross-license is an agreement between firms that are often actual or potential competitors, it can cross into illegality if it is used as a vehicle for, or has the effect of, anticompetitive conduct. The danger zones: (1) Price-fixing or output coordination — a cross-license cannot be a cover for competitors agreeing on the prices, output, or terms of their downstream products; if the licensing arrangement facilitates such coordination, it is unlawful regardless of the IP wrapper. (2) Market or customer allocation — using field-of-use or territorial restrictions in a cross-license to divide markets between competitors (rather than to tailor genuine licensing scope) can be illegal market division. (3) Foreclosure of rivals — a cross-license (or a web of them) structured to exclude or disadvantage non-party competitors, or to deny them access to essential technology, raises monopolization and exclusion concerns. (4) Grant-back and pooling abuses — overly broad exclusive grant-backs that suppress innovation, or cross-licenses that function as disguised price-fixing pools of substitute patents. (5) Sham or reverse-payment settlements — in the pharmaceutical context, 'pay-for-delay' settlements where a brand pays a generic to stay out of the market have drawn antitrust scrutiny (FTC v. Actavis, U.S. 2013), and cross-license terms can be part of such scrutinized deals. The guiding principle: a cross-license that licenses genuine technology to enable both parties to operate is fine; one whose real purpose or effect is to soften competition, divide markets, or exclude rivals is not. Companies doing significant cross-licenses, especially between major competitors or involving standard-essential patents, routinely involve antitrust counsel.